Pretax income is the income that a company earns before paying income taxes. Xencor's pretax income for the
three
months ended in Mar. 2024 was $-68.7 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-128.4 Mil.
Xencor's pretax margin was -536.58%.
During the past 13 years, Xencor's highest Pretax Margin was 42.30%. The lowest was -173.41%. And the median was -59.94%.
Xencor Pre-Tax Income Historical Data
The historical data trend for Xencor's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xencor's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xencor's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xencor's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Xencor's Pre-Tax Income falls into.
Xencor Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Xencor's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-128.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xencor (NAS:XNCR) Pre-Tax Income Explanation
Xencor's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 13 years, Xencor's highest Pretax Margin was 42.30%. The lowest was -173.41%. And the median was -59.94%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xencor Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Xencor's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XNCR has been successfully added to your 